Basel, Switzerland

Marta Cortes-Cros

USPTO Granted Patents = 1 

 

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 7(Granted Patents)


Company Filing History:


Years Active: 2012

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Marta Cortes-Cros: Innovator in Pharmaceutical Applications

Introduction

Marta Cortes-Cros is a prominent inventor based in Basel, Switzerland. She has made significant contributions to the field of pharmaceuticals, particularly in the development of binding molecules for therapeutic use. Her work focuses on advancing treatments for diseases associated with axonal degeneration and demyelination.

Latest Patents

Marta holds a patent for "LINGO binding molecules and pharmaceutical use thereof." This invention provides a binding molecule capable of binding to the rat, cynomolgus monkey, and human LINGO polypeptide. It also includes a polynucleotide encoding the binding molecule, an expression vector, and an expression system for producing the binding molecule. The invention outlines compositions comprising the LINGO binding molecules and their use as pharmaceuticals, especially in promoting axonal regeneration and plasticity.

Career Highlights

Marta Cortes-Cros is associated with Novartis AG, a leading global healthcare company. Her work at Novartis has allowed her to contribute to innovative solutions in the pharmaceutical industry. With a focus on research and development, she has played a vital role in advancing medical treatments.

Collaborations

Marta has collaborated with notable colleagues, including Adrian Walmsley and William Leonard Wishart. These partnerships have enhanced her research efforts and contributed to the success of her inventions.

Conclusion

Marta Cortes-Cros is a distinguished inventor whose work in binding molecules has the potential to transform treatments for neurological diseases. Her contributions to Novartis AG and the pharmaceutical field underscore her commitment to innovation and improving patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…